228 related articles for article (PubMed ID: 21511220)
1. Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations.
Angiolillo DJ; Ueno M
JACC Cardiovasc Interv; 2011 Apr; 4(4):411-4. PubMed ID: 21511220
[No Abstract] [Full Text] [Related]
2. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A
JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219
[TBL] [Abstract][Full Text] [Related]
3. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
Kim IS; Jeong YH; Park Y; Park KS; Yun SE; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
JACC Cardiovasc Interv; 2011 Apr; 4(4):381-91. PubMed ID: 21511217
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic effect of clopidogrel therapy and switching to cilostazol in patients with the CYP2C19 loss-of-function allele (ACCEL-SWITCH) study.
Jeong YH; Park Y; Muse WC; Kwon TJ; Koh JS; Hwang SJ; Kwak CH; Hwang JY
J Thromb Haemost; 2012 Aug; 10(8):1685-8. PubMed ID: 22612904
[No Abstract] [Full Text] [Related]
5. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).
Collet JP; Hulot JS; Anzaha G; Pena A; Chastre T; Caron C; Silvain J; Cayla G; Bellemain-Appaix A; Vignalou JB; Galier S; Barthélémy O; Beygui F; Gallois V; Montalescot G;
JACC Cardiovasc Interv; 2011 Apr; 4(4):392-402. PubMed ID: 21511218
[TBL] [Abstract][Full Text] [Related]
6. The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient.
Gurbel PA; Tantry US; Shuldiner AR
JACC Cardiovasc Interv; 2009 Nov; 2(11):1102-4. PubMed ID: 19926051
[No Abstract] [Full Text] [Related]
7. Can we override clopidogrel resistance?
Pena A; Collet JP; Hulot JS; Silvain J; Barthélémy O; Beygui F; Funck-Brentano C; Montalescot G
Circulation; 2009 Jun; 119(21):2854-7. PubMed ID: 19487603
[No Abstract] [Full Text] [Related]
8. Acceptance of high platelet reactivity as a risk factor: now, what do we do about it?
Gurbel PA; Tantry US
JACC Cardiovasc Interv; 2010 Oct; 3(10):1008-10. PubMed ID: 20965457
[No Abstract] [Full Text] [Related]
9. Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study.
Fontana P; James R; Barazer I; Berdagué P; Schved JF; Rebsamen M; Vuilleumier N; Reny JL
J Thromb Haemost; 2011 Aug; 9(8):1664-6. PubMed ID: 21692977
[No Abstract] [Full Text] [Related]
10. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.
Price MJ; Tantry US; Gurbel PA
Rev Cardiovasc Med; 2011; 12(1):1-12. PubMed ID: 21546883
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics: Point-of-care genetic testing--a new frontier explored.
Barrett PM; Topol EJ
Nat Rev Cardiol; 2012 May; 9(6):315-6. PubMed ID: 22547169
[No Abstract] [Full Text] [Related]
12. Searching for the ceiling: new reflections on the disposition and metabolism of clopidogrel.
Kleiman NS
JACC Cardiovasc Interv; 2008 Dec; 1(6):628-30. PubMed ID: 19463376
[No Abstract] [Full Text] [Related]
13. Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study.
Gladding P; White H; Voss J; Ormiston J; Stewart J; Ruygrok P; Bvaldivia B; Baak R; White C; Webster M
JACC Cardiovasc Interv; 2009 Nov; 2(11):1095-101. PubMed ID: 19926050
[TBL] [Abstract][Full Text] [Related]
14. Antiplatelet therapy: Does CYP2C19 genotype affect clinical outcome?
ten Berg JM; Deneer VH
Nat Rev Cardiol; 2012 Mar; 9(4):192-4. PubMed ID: 22411289
[No Abstract] [Full Text] [Related]
15. Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle.
Fuster V; Sweeny JM
JAMA; 2010 Oct; 304(16):1839-40. PubMed ID: 20978263
[No Abstract] [Full Text] [Related]
16. The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.
Hwang SJ; Jeong YH; Kim IS; Koh JS; Kang MK; Park Y; Kwak CH; Hwang JY
Thromb Res; 2011 Jan; 127(1):23-8. PubMed ID: 21075428
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
[TBL] [Abstract][Full Text] [Related]
18. Clopidogrel Resistance: case reports of CYP2C19 gene variants in suspected coronary stent thrombosis.
Dick RJ; Dear AE; Byron KA
Heart Lung Circ; 2011 Oct; 20(10):657-8. PubMed ID: 21215696
[TBL] [Abstract][Full Text] [Related]
19. Clopidogrel poor metabolizers may need alternative to standard regimen.
Thompson CA
Am J Health Syst Pharm; 2010 May; 67(10):779-80. PubMed ID: 20479095
[No Abstract] [Full Text] [Related]
20. Bedside evaluation of thienopyridine antiplatelet therapy.
Price MJ
Circulation; 2009 May; 119(19):2625-32. PubMed ID: 19451364
[No Abstract] [Full Text] [Related]
[Next] [New Search]
